StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$13.62+0.77 (+5.99%)

Close on Nov 18, 2026Market cap $182.28MP/E –Yield –

Anika Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Anika Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $120.65M, up 5.3% year over year. For fiscal 2025 it was $112.82M, down 5.9% from the year before. Over ten years it grew 2.0% a year on average. The highest annual figure on record is $147.79M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$112.82M-5.9%
FY2024Dec 31, 2024$119.91M-0.7%
FY2023Dec 31, 2023$120.79M+6.1%
FY2022Dec 31, 2022$113.83M-23.0%
FY2021Dec 31, 2021$147.79M+13.3%
FY2020Dec 31, 2020$130.46M+13.8%
FY2019Dec 31, 2019$114.61M+8.6%
FY2018Dec 31, 2018$105.56M-6.9%
FY2017Dec 31, 2017$113.42M+9.7%
FY2016Dec 31, 2016$103.38M+11.2%
FY2015Dec 31, 2015$93.00M-11.9%
FY2014Dec 31, 2014$105.60M+40.6%
FY2013Dec 31, 2013$75.08M+5.2%
FY2012Dec 31, 2012$71.36M+10.2%
FY2011Dec 31, 2011$64.78M+16.6%
FY2010Dec 31, 2010$55.56M+38.4%
FY2009Dec 31, 2009$40.14M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$32.61M+15.6%
Q1 FY2026Mar 31, 2026$29.61M+13.2%
Q4 FY2025Dec 31, 2025$30.62M+0.0%
Q3 FY2025Sep 30, 2025$27.82M-5.9%
Q2 FY2025Jun 30, 2025$28.22M-8.2%
Q1 FY2025Mar 31, 2025$26.17M-9.8%
Q4 FY2024Dec 31, 2024$30.60M-28.8%
Q3 FY2024Sep 30, 2024$29.56M-28.7%
Q2 FY2024Jun 30, 2024$30.72M-30.6%
Q1 FY2024Mar 31, 2024$29.02M-23.5%
Q4 FY2023Dec 31, 2023$42.97M+8.5%
Q3 FY2023Sep 30, 2023$41.47M+3.0%
Q2 FY2023Jun 30, 2023$44.30M+11.7%
Q1 FY2023Mar 31, 2023$37.92M+3.4%
Q4 FY2022Dec 31, 2022$39.62M+10.6%
Q3 FY2022Sep 30, 2022$40.26M+1.8%
Q2 FY2022Jun 30, 2022$39.66M+4.0%
Q1 FY2022Mar 31, 2022$36.69M+7.0%
Q4 FY2021Dec 31, 2021$35.82M+9.6%
Q3 FY2021Sep 30, 2021$39.54M+24.7%
Q2 FY2021Jun 30, 2021$38.15M+24.3%
Q1 FY2021Mar 31, 2021$34.29M-3.1%
Q4 FY2020Dec 31, 2020$32.69M+9.8%
Q3 FY2020Sep 30, 2020$31.69M+6.7%
Q2 FY2020Jun 30, 2020$30.68M+0.9%
Q1 FY2020Mar 31, 2020$35.40M+43.2%
Q4 FY2019Dec 31, 2019$29.77M+10.4%
Q3 FY2019Sep 30, 2019$29.70M+10.9%
Q2 FY2019Jun 30, 2019$30.42M-0.4%
Q1 FY2019Mar 31, 2019$24.72M+16.3%
Q4 FY2018Dec 31, 2018$26.96M-8.3%
Q3 FY2018Sep 30, 2018$26.79M-1.5%
Q2 FY2018Jun 30, 2018$30.55M-8.7%
Q1 FY2018Mar 31, 2018$21.26M-9.1%
Q4 FY2017Dec 31, 2017$29.39M+2.3%
Q3 FY2017Sep 30, 2017$27.18M+5.4%
Q2 FY2017Jun 30, 2017$33.46M–
Q1 FY2017Mar 31, 2017$23.39M–
Q4 FY2016Dec 31, 2016$28.73M–
Q3 FY2016Sep 30, 2016$25.79M–

More Anika Therapeutics figures

See a number that looks wrong?